Lin WengJingjing YeFenghe YangShi JiaMinghong LengBo JiaChunling XuYang ZhaoRuxia LiuYufei XiongYiqing ZhouJunhui ZhaoMing ZhengDepartment of Physiology and Pathophysiology,School of Basic Medical Sciences,Peking University Health Science Center,and State Key Laboratory of Vascular Homeostasis and Remodeling,Peking University,Beijing,China (L.W.,F.Y.,S.J.,M.L.,C.X.,R.L.,Y.X.,Y. Zhao,J.Z.,M.Z.).Trauma Medicine Center,Peking University People's Hospital,Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University),National Center for Trauma Medicine,Beijing,China (J.Y.,B.J.).Department of Laboratory Medicine,Peking University Third Hospital,Beijing,China (Y. Zhou).

Abstract:Circulation Research, Ahead of Print. BACKGROUND:Progressive cardiac fibrosis leads to ventricular wall stiffness, cardiac dysfunction, and eventually heart failure, but the underlying mechanism remains unexplored. PDCD5 (programmed cell death 5) ubiquitously expresses in tissues, including the heart; however, the role of PDCD5 in cardiac fibrosis is largely unknown. Therefore, this study aims at exploring the possible role and underlying mechanisms of PDCD5 in the pathogenesis of cardiac fibrosis.METHODS AND RESULTS:PDCD5 levels were found to be elevated in the serum obtained from patients with cardiac fibrosis, in fibrotic mice heart tissues after myocardial infarction, and in cardiac fibroblasts stimulated by Ang II (angiotensin II)- or TGF-β1 (transforming growth factor-β1). Overexpression of PDCD5 in cardiac fibroblasts or treatment with PDCD5 protein reduced the expression of profibrogenic proteins in response to TGF-β1 stimulation, while knockdown of PDCD5 increased fibrotic responses. It has been demonstrated that SMAD3, a protein that is also known as mothers against decapentaplegic homolog 3, directly upregulated PDCD5 during cardiac fibrosis. Subsequently, the increased PDCD5 promoted HDAC3 (histone deacetylase 3) ubiquitination, thus, inhibiting HDAC3 to reduce fibrotic responses. Fibroblast-specific knock-in of PDCD5 in mice ameliorated cardiac fibrosis after myocardial infarction and enhanced cardiac function, and these protective effects were eliminated by AAV9-mediated HDAC3 overexpression.CONCLUSIONS:The findings of this study demonstrated that PDCD5 is upregulated by SMAD3 during cardiac fibrosis, which subsequently ameliorated progressive fibrosis and cardiac dysfunction through HDAC3 inhibition. Thus, this study suggests that PDCD5 functions as a negative feedback factor on fibrotic signaling pathways and might serve as a potential therapeutic target to suppress the progression of fibrotic responses.

Programmed Cell Death 5 Provides Negative Feedback on Cardiac Hypertrophy Through the Stabilization of Sarco/Endoplasmic Reticulum Ca2+-ATPase 2a Protein

Downregulation Of Cypher Induces Apoptosis In Cardiomyocytes Via Akt/P38 Mapk Signaling Pathway

Inhibition of TRPC1 Prevents Cardiac Hypertrophy Via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Muscle-specific programmed cell death 5 deletion attenuates cardiac aging

Cardiac‐specific Deletion of FDPS Induces Cardiac Remodeling and Dysfunction by Enhancing the Activity of Small GTP‐binding Proteins

PDCD5 Protects Against Cardiac Remodeling by Regulating Autophagy and Apoptosis

Involvement Of Autophagy In Cardiac Remodeling In Transgenic Mice With Cardiac Specific Over-Expression Of Human Programmed Cell Death 5

Reply To: Muscle-specific Programmed Cell Death 5 in Heart Disease: Friend or Foe?

TGF-β1/SMAD3 Regulates Programmed Cell Death 5 That Suppresses Cardiac Fibrosis Post–Myocardial Infarction by Inhibiting HDAC3

Unmasking Protein Phosphatase 2A Regulatory Subunit B as a Crucial Factor in the Progression of Dilated Cardiomyopathy

Programmed cell death 5 improves skeletal muscle insulin resistance by inhibiting IRS-1 ubiquitination through stabilization of MDM2

C/EBPβ Knockdown Protects Cardiomyocytes from Hypertrophy Via Inhibition of P65-Nfκb.

Programmed Exercise Attenuates Familial Hypertrophic Cardiomyopathy in Transgenic E22K Mice <i>via</i> Inhibition of PKC-/NFAT Pathway

Peroxisome proliferator–activated receptor gamma coactivator 1 alpha protects cardiomyocytes from hypertrophy by suppressing calcineurin-nuclear factor of activated T cells c4 signaling pathway

Programmed Exercise Attenuates Familial Hypertrophic Cardiomyopathy in Transgenic E22K Mice via Inhibition of PKC-α/NFAT Pathway

Novel Role for Caspase-Activated DNase in the Regulation of Pathological Cardiac Hypertrophy.

Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure

Protein Kinase D3 is a Pivotal Activator of Pathological Cardiac Hypertrophy by Selectively Increasing the Expression of Hypertrophic Transcription Factors

Deubiquitinating enzyme CYLD mediates pressure overload-induced cardiac maladaptive remodeling and dysfunction via downregulating Nrf2

Sirtuin 1 Represses PKC‐ζ Activity Through Regulating Interplay of Acetylation and Phosphorylation in Cardiac Hypertrophy

Combined Cardiomyocyte PKCδ and PKCε Gene Deletion Uncovers Their Central Role in Restraining Developmental and Reactive Heart Growth